Myeloma

Type of Cancer: Phase 1-2 trial evaluating anti-TGF agent (SAR439459) or pomalidomide in combination with isatuximab and dexamethasone in relapsed or refractory multiple myeloma (RRMM).

Sponsor: Sanofi

Phase / Design:

Population:

Hepatocellular
Breast Cancer
Menu